Hubert Czerniak TV - Jaki olejek CBD wybrać? Jak i na co stosować? Olej czy susz? Wszystko o #CBD

The speaker contrasts the Israeli approach, where patients can legally obtain a prescription for cannabis flower and are instructed to vaporize it rather than smoke it, with the restrictive policies elsewhere. He notes that the Israeli Ministry of Health has been discussing these matters for years, and the practice is normalised there. The 200°C threshold is derived from the need to avoid pyrolysis of plant material, which would produce carcinogens and irritants typical of smoke. By staying at this temperature, the user gets the therapeutic benefits of cannabinoids – many of which have boiling points around 160–220°C – without the toxic load. This method is part of a harm‑reduction strategy that acknowledges the medical value of the plant while mitigating the risks associated with its administration.

The speaker references studies from the Hebrew University of Jerusalem where CBD was found to produce ‘beautiful healing’ in schizophrenia. He underscores that 800 mg is a substantial dose, and that this quantity is necessary to achieve the antipsychotic effect. The underlying mechanism is an elevation of anandamide, which has a calming, homeostatic role in the brain. However, the speaker laments the political economy of medicine: because CBD is a natural substance, it cannot be patented, and therefore there is no lucrative market incentive to develop and distribute it as a registered medication. He draws a parallel with cortisone, where the natural hormone is unavailable, but a semi‑synthetic derivative is profitable and widely marketed. This protocol remains largely unavailable to patients because of these regulatory and economic barriers, not because of lack of efficacy.

The speaker presents a multi‑layered anti‑inflammatory argument. First, CBD lowers the production of pro‑inflammatory bio‑messengers (cytokines) and shifts the immune response toward a less aggressive profile. Second, it reduces the expression of genes coding for inflammatory factors, meaning that at a transcriptional level, the machinery of inflammation is dialled down. Third, CBD acts on CB2 receptors that are abundant on immune cells (B‑lymphocytes, macrophages, monocytes) in peripheral tissues and the spleen, directly regulating the immune response. He specifically calls out ‘so‑called incurable diseases’ – Hashimoto’s, lupus, scleroderma – and asserts that they can be treated with cannabinoid preparations. The speaker also connects this to microglial inflammation in the brain, which is implicated in autism; by inhibiting CB2 receptor overstimulation on microglia, CBD protects neural tissue from damage. This protocol is presented as a necessary and logical step for any practitioner who genuinely wants to treat these conditions, rather than merely managing symptoms with drugs that have more side effects.

The speaker directly challenges paediatric neurologists at leading Polish children’s hospitals (Centrum Zdrowia Dziecka, Centrum Zdrowia Matki Polki), asking why they ‘stuff’ children with GABAergic drugs when a natural substance could be used with ‘beautiful effects’. He cites the experience of Professor Bachański, a known proponent of medical cannabis in Poland, as evidence that CBD works in practice. He explains that CB1 receptors are present in layers I and IV of the cerebral cortex, and their activation inhibits epileptic discharges. Moreover, CBD’s action on the GABAergic system – the brain’s main inhibitory network – provides an anticonvulsant mechanism without the extrapyramidal (movement disorder) side effects that often accompany traditional anti‑epileptics. The speaker frames this as a matter of medical ethics: denying children a safe, effective therapy in favour of neuroleptics that ‘stupefy’ them is, in his view, indefensible.

The speaker argues that the ECS is the body’s most abundant receptor system, surpassing adrenergic, dopaminergic, and serotonergic systems in number. CB1 receptors are found in the cerebral cortex (layers I and IV), cerebellum, basal ganglia, spinal cord, heart, lungs, liver, kidneys, adipose tissue, prostate, testes, and ovaries, influencing movement coordination, appetite (especially for sweets), and pain perception. CB2 receptors are predominantly on hematopoietic cells, peripheral nervous system, leukocytes, B‑lymphocytes, macrophages, monocytes, spleen, and tonsils, modulating immune responses. Despite this ubiquity and its involvement in stress, anxiety, and neuroprotection, the ECS is not taught in medical schools. The speaker asserts this is a direct consequence of the fact that cannabinoid therapies, being natural, cannot be patented and therefore lack the financial incentive that drives pharmaceutical education. He draws a parallel with herbs, which were similarly marginalised in his previous talk.

When a woman breastfeeds, she secretes both anandamide and 2‑AG, which the speaker claims directly produce the infant’s feeling of well‑being and the mother‑child bond. Similarly, during meditation the same endocannabinoids are produced, contributing to a state of deep calm and bliss. The ‘high’ experienced during strenuous exercise – previously attributed to endorphins – is now understood by the speaker as a result of endocannabinoid release, specifically the emotion, fight, and will to win. He links this to the broader function of the ECS in inhibiting negative emotions and maintaining psychological equilibrium. A deficiency in endocannabinoid production or a scarcity of CB1/CB2 receptors, according to the speaker, can lead to post‑traumatic stress disorder, underscoring the system’s role in emotional homeostasis.

Rafael Mechoulam’s group at the Hebrew University of Jerusalem found that CBD is effective in schizophrenia models. They concluded that CBD increases the concentration of anandamide, the endocannabinoid that acts on CB1 and CB2 receptors. The speaker points out that the dose required was 800 mg of pure cannabidiol, a relatively high amount. Despite the promising results, the fact that CBD is a natural compound means it cannot be patented; consequently, there is no pharmaceutical blockbuster, and the treatment remains underutilised. The speaker compares this situation with that of cortisone, where the natural hormone is unpatentable but its patented derivative earns 5–6 million dollars annually per brand. He criticises the legal and economic barriers that prevent patients from accessing effective natural therapies.

The speaker explains that glutamate and aspartate are not only flavour enhancers acting on umami taste receptors but also major excitatory neurotransmitters in the brain. Overstimulation of glutamate receptors, particularly NMDA receptors, leads to neuronal hyperexcitability – a core feature in autism, involuntary movements, and ADHD. CBD, by slowing the glutamatergic system, can dampen this pathological excitation. The speaker frames this as an indispensable therapeutic tool: ‘Jeżeli chcemy leczyć dzieci, to musimy tego użyć. Nie ma innej możliwości.’ He sharply criticises the use of neuroleptics and psychotropics that, in his words, ‘stupify’ children. This is presented as a safer, mechanism‑based alternative that preserves cognitive function while calming the nervous system.